Glen Eagle Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.19M | Sell |
3,464
-227
| -6% | -$230K | 0.45% | 42 |
|
|
2025
Q4 | $3.97M | Buy |
3,691
+56
| +2% | +$53.5K | 0.54% | 38 |
|
|
2025
Q3 | $2.77M | Buy |
3,635
+1
| +0% | +$744 | 0.39% | 48 |
|
|
2025
Q2 | $2.83M | Sell |
3,634
-2
| -0.1% | -$1.55K | 0.44% | 42 |
|
|
2025
Q1 | $3M | Buy |
3,636
+137
| +4% | +$114K | 0.5% | 42 |
|
|
2024
Q4 | $2.7M | Buy |
3,499
+20
| +0.6% | +$16.6K | 0.45% | 46 |
|
|
2024
Q3 | $3.08M | Buy |
3,479
+50
| +1% | +$45K | 0.52% | 43 |
|
|
2024
Q2 | $3.1M | Buy |
3,429
+182
| +6% | +$146K | 0.57% | 37 |
|
|
2024
Q1 | $2.53M | Buy |
3,247
+209
| +7% | +$149K | 0.48% | 47 |
|
|
2023
Q4 | $1.77M | Sell |
3,038
-158
| -5% | -$92.2K | 0.37% | 57 |
|
|
2023
Q3 | $1.72M | Sell |
3,196
-1,206
| -27% | -$621K | 0.4% | 54 |
|
|
2023
Q2 | $2.06M | Buy |
4,402
+93
| +2% | +$39K | 0.48% | 48 |
|
|
2023
Q1 | $1.48M | Buy |
4,309
+865
| +25% | +$292K | 0.37% | 59 |
|
|
2022
Q4 | $1.26M | Buy |
3,444
+1,239
| +56% | +$439K | 0.34% | 63 |
|
|
2022
Q3 | $713K | Buy |
2,205
+1,236
| +128% | +$392K | 0.21% | 97 |
|
|
2022
Q2 | $314K | Buy |
969
+57
| +6% | +$17.1K | 0.09% | 174 |
|
|
2022
Q1 | $261K | Sell |
912
-7
| -0.8% | -$1.8K | 0.07% | 200 |
|
|
2021
Q4 | $254K | Sell |
919
-62
| -6% | -$15.7K | 0.07% | 201 |
|
|
2021
Q3 | $227K | Buy |
981
+106
| +12% | +$26.2K | 0.07% | 198 |
|
|
2021
Q2 | $201K | Hold |
875
| – | – | 0.06% | 209 |
|
|
2021
Q1 | $163K | Buy |
875
+65
| +8% | +$12.7K | 0.06% | 210 |
|
|
2020
Q4 | $137K | Buy |
810
+11
| +1% | +$1.64K | 0.05% | 205 |
|
|
2020
Q3 | $118K | Sell |
799
-9
| -1% | -$1.39K | 0.05% | 206 |
|
|
2020
Q2 | $133K | Buy |
808
+3
| +0.4% | +$460 | 0.07% | 182 |
|
|
2020
Q1 | $112K | Buy |
805
+24
| +3% | +$3.3K | 0.08% | 181 |
|
|
2019
Q4 | $103K | Buy |
781
+81
| +12% | +$9.39K | 0.05% | 222 |
|
|
2019
Q3 | $78.3K | Hold |
700
| – | – | 0.05% | 230 |
|
|
2019
Q2 | $77.6K | Buy |
700
+95
| +16% | +$11.2K | 0.05% | 225 |
|
|
2019
Q1 | $78.5K | Hold |
605
| – | – | 0.06% | 222 |
|
|
2018
Q4 | $70K | Hold |
605
| – | – | 0.06% | 218 |
|
|
2018
Q3 | $64.9K | Sell |
605
-100
| -14% | -$10K | 0.05% | 236 |
|
|
2018
Q2 | $60.2K | Hold |
705
| – | – | 0.05% | 242 |
|
|
2018
Q1 | $54.5K | Sell |
705
-17
| -2% | -$1.37K | 0.05% | 240 |
|
|
2017
Q4 | $61K | Hold |
722
| – | – | 0.05% | 229 |
|
|
2017
Q3 | $61.8K | Hold |
722
| – | – | 0.06% | 221 |
|
|
2017
Q2 | $59.4K | Hold |
722
| – | – | 0.05% | 204 |
|
|
2017
Q1 | $60.7K | Sell |
722
-291
| -29% | -$23.3K | 0.05% | 189 |
|
|
2016
Q4 | $74.5K | Buy |
+1,013
| New | +$75.4K | 0.07% | 173 |
|
Other funds holding LLY
VCM
VPM
Glen Eagle Advisors's LLY Position: Q1 2026 in Review
Glen Eagle Advisors reduced its Eli Lilly (LLY) stake by 6.2% in Q1 2026, selling an estimated $230K and leaving 3,464 shares worth $3.19M. The position accounts for 0.45% of the portfolio, ranked #42.
Glen Eagle Advisors first reported a position in LLY in Q4 2016 and has held it in 38 quarters since. The position peaked at $3.97M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Glen Eagle Advisors held 3,464 shares of Eli Lilly worth $3.19M as of Q1 2026.
- Glen Eagle Advisors sold 227 Eli Lilly shares in Q1 2026, an estimated $230K.
- Eli Lilly made up 0.45% of Glen Eagle Advisors's portfolio in Q1 2026, its #42 holding.
- Glen Eagle Advisors first reported a position in Eli Lilly in Q4 2016 and has held it in 38 quarters since.
- Glen Eagle Advisors's Eli Lilly position peaked at $3.97M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.